A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

Phase 1CompletedNCT02919319

Idorsia Pharmaceuticals Ltd.40 enrolled

Overview

The main objectives of this first-into-man study were to investigate the safety, tolerability and the pharmacokinetic profile of single oral doses of ACT-541468 in healthy male adults. Pharmacodynamic effects (through a battery of Central Nervous System tests) were also assessed.

The study consisted of ascending dose groups; each dose group was investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo). In addition, the study included a biocomparison part (dose group 2), an absolute bioavailability part (dose group 4), and a mass balance / metabolism part (dose group 3).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

TRIPLE

Enrollment

Conditions

Healthy Subjects

Interventions

ACT-541468 (Formulation A)DRUG

Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg

ACT-541468 (Formulation B)DRUG

Soft gelatin capsules for oral administration formulated at the strength of 25 mg

Placebo (Formulation A)DRUG

Hard capsules matching ACT-541468 Formulation A

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Key inclusion Criteria: * Signed informed consent prior to any study-mandated procedure. * Males aged from 18 to 45 years (inclusive) at screening. * Body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening. * Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) between 100-145 mmHg, 50-90 mmHg and 45-90 bpm (all inclusive) at screening, respectively. * Healthy on the basis of physical examination,electrocardiogram and laboratory tests. Key exclusion Criteria: * Known hypersensitivity to any excipients of the drug formulations. * History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs. * History of narcolepsy or cataplexy or modified Swiss narcolepsy scale total score \< 0 at screening. * Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Locations (1)

Investigator Site

Leiden, Netherlands

Outcomes

Primary Outcomes

Number of subjects with treatment-emergent adverse events and serious adverse events

Collection of any adverse event at each dose level

Time frame: Day 8